These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18367000)

  • 1. Fatty liver, insulin resistance, and dyslipidemia.
    Adiels M; Taskinen MR; Borén J
    Curr Diab Rep; 2008 Feb; 8(1):60-4. PubMed ID: 18367000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model.
    Zago V; Lucero D; Macri EV; Cacciagiú L; Gamba CA; Miksztowicz V; Berg G; Wikinski R; Friedman S; Schreier L
    Ann Nutr Metab; 2010; 56(3):198-206. PubMed ID: 20203480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
    Cohen DE; Fisher EA
    Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.
    Qin B; Anderson RA; Kuzuya T; Kitaura Y; Shimomura Y
    Atherosclerosis; 2012 Jun; 222(2):409-16. PubMed ID: 22546076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.
    Taher J; Baker C; Alvares D; Ijaz L; Hussain M; Adeli K
    Endocrinology; 2018 Sep; 159(9):3340-3350. PubMed ID: 30052880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G
    Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
    Kwiterovich PO
    Am J Cardiol; 2002 Oct; 90(8A):30i-47i. PubMed ID: 12419479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia in patients with nonalcoholic fatty liver disease.
    Chatrath H; Vuppalanchi R; Chalasani N
    Semin Liver Dis; 2012 Feb; 32(1):22-9. PubMed ID: 22418885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.
    Julius U
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):246-50. PubMed ID: 12951628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging regulators of intestinal lipoprotein secretion.
    Xiao C; Dash S; Morgantini C; Lewis GF
    Atherosclerosis; 2014 Apr; 233(2):608-615. PubMed ID: 24534456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of plasma triglycerides in insulin resistance and diabetes.
    Ginsberg HN; Zhang YL; Hernandez-Ono A
    Arch Med Res; 2005; 36(3):232-40. PubMed ID: 15925013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance.
    Adeli K; Taghibiglou C; Van Iderstine SC; Lewis GF
    Trends Cardiovasc Med; 2001 Jul; 11(5):170-6. PubMed ID: 11597827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol extract of North American ginseng (Panax quinquefolius) reduces fatty liver, dyslipidemia, and other complications of metabolic syndrome in a mouse model.
    Singh RK; Lui E; Wright D; Taylor A; Bakovic M
    Can J Physiol Pharmacol; 2017 Sep; 95(9):1046-1057. PubMed ID: 28666094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states.
    Farr S; Taher J; Adeli K
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(2):126-36. PubMed ID: 24801723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.
    Fabbrini E; Mohammed BS; Magkos F; Korenblat KM; Patterson BW; Klein S
    Gastroenterology; 2008 Feb; 134(2):424-31. PubMed ID: 18242210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes as a lipid disorder.
    Taskinen MR
    Curr Mol Med; 2005 May; 5(3):297-308. PubMed ID: 15892649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
    Khound R; Taher J; Baker C; Adeli K; Su Q
    Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2252-2259. PubMed ID: 29074588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.